FR2277089B1 - - Google Patents

Info

Publication number
FR2277089B1
FR2277089B1 FR7521043A FR7521043A FR2277089B1 FR 2277089 B1 FR2277089 B1 FR 2277089B1 FR 7521043 A FR7521043 A FR 7521043A FR 7521043 A FR7521043 A FR 7521043A FR 2277089 B1 FR2277089 B1 FR 2277089B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7521043A
Other versions
FR2277089A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/485,869 external-priority patent/US4108995A/en
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of FR2277089A1 publication Critical patent/FR2277089A1/fr
Application granted granted Critical
Publication of FR2277089B1 publication Critical patent/FR2277089B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
FR7521043A 1974-07-05 1975-07-04 Procede de preparation de derives de la xanthine et composes pour sa mise en oeuvre Granted FR2277089A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48587074A 1974-07-05 1974-07-05
US05/485,869 US4108995A (en) 1973-07-11 1974-07-05 Hydroxyhexyl-alkylxanthines and pharmaceutical compositions containing hydroxyhexyl-alkylxanthines

Publications (2)

Publication Number Publication Date
FR2277089A1 FR2277089A1 (fr) 1976-01-30
FR2277089B1 true FR2277089B1 (fr) 1978-03-17

Family

ID=27048497

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7521043A Granted FR2277089A1 (fr) 1974-07-05 1975-07-04 Procede de preparation de derives de la xanthine et composes pour sa mise en oeuvre

Country Status (14)

Country Link
JP (1) JPS5250800B2 (fr)
AR (1) AR210330A1 (fr)
AT (1) AT339917B (fr)
CA (1) CA1062710A (fr)
CH (2) CH622519A5 (fr)
DK (1) DK140214B (fr)
ES (1) ES439141A1 (fr)
FI (1) FI59249C (fr)
FR (1) FR2277089A1 (fr)
GB (1) GB1500039A (fr)
LU (1) LU72897A1 (fr)
NL (1) NL166476C (fr)
NO (1) NO143224C (fr)
SE (2) SE420097B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664568A5 (de) * 1984-01-12 1988-03-15 Sandoz Ag 8-alpha-acylaminoergoline.
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
EP0570831A2 (fr) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Utilisation de dérivés de Xanthine pour le traitement de dommages cérébraux après interruption de la circulation sanguine

Also Published As

Publication number Publication date
NL7507976A (nl) 1976-01-07
CA1062710A (fr) 1979-09-18
ES439141A1 (es) 1977-02-16
FI59249C (fi) 1981-07-10
FI59249B (fi) 1981-03-31
SE427183B (sv) 1983-03-14
NO143224C (no) 1981-01-02
CH622018A5 (en) 1981-03-13
JPS5250800B2 (fr) 1977-12-27
GB1500039A (en) 1978-02-08
NO752423L (fr) 1976-01-06
FR2277089A1 (fr) 1976-01-30
DK140214C (fr) 1979-12-03
SE420097B (sv) 1981-09-14
NO143224B (no) 1980-09-22
AU8275575A (en) 1977-01-06
FI751958A (fr) 1976-01-06
ATA517275A (de) 1977-03-15
CH622519A5 (en) 1981-04-15
NL166476B (nl) 1981-03-16
SE7507726L (sv) 1976-01-06
LU72897A1 (fr) 1976-05-31
JPS5134194A (fr) 1976-03-23
AR210330A1 (es) 1977-07-29
DK140214B (da) 1979-07-09
AT339917B (de) 1977-11-10
SE7807853L (sv) 1978-07-14
DK301775A (fr) 1976-01-06
NL166476C (nl) 1981-08-17

Similar Documents

Publication Publication Date Title
JPS5134194A (fr)
FR2266508B1 (fr)
FR2273912B1 (fr)
AU7034374A (fr)
BG20649A1 (fr)
BG20653A1 (fr)
BG20840A1 (fr)
BG20945A1 (fr)
BG21310A1 (fr)
BG21514A1 (fr)
BG21753A1 (fr)
BG22107A1 (fr)
BG22305A1 (fr)
BG23208A3 (fr)
BG26201A3 (fr)
BG27068A3 (fr)
CH1147874A4 (fr)
CH1468974A4 (fr)
CH199074A4 (fr)
CH51275A4 (fr)
CH561530A5 (fr)
CH568044A5 (fr)
CH570108A5 (fr)
CH570727A5 (fr)
CH573779A5 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse